Debt Woes

Glenmark Pharmaceuticals aims to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year, according to Chairman and Managing Director Glenn Saldanha. The Mumbai-based drug major is also looking at enhancing EBITDA margins while expanding presence in various therapeutic segments like oncology and dermatology. "For the new financial year, we aim to grow by 10-11 per cent in revenues, expand our EBITDA margin to 19-20 per cent, and continue to focus on enhancing free cash generation for further debt reduction," Saldanha said in the company's Annual Report for FY23. In FY23, the company's consolidated revenue from operations stood at Rs 12,990 crore, up from Rs 12,305 crore in FY22. Besides, the drug maker reported an EBITDA of Rs 2,278 crore during the 2022-23 fiscal with margins at 17.5 per cent. Glenmark reported net debt of Rs 2,905 crore for the fiscal ended March 31, 2023. Addressing the company's shareholders, he not

Emerging markets across the world have been devastated by surging commodity prices following Russia's invasion of Ukraine

The most-expensive-debt first approach is cost-effective, while debt snowball has been found to be the most successful

One possibility is that the size of borrowings year-on-year will remain high and there is unlikely to be a reduction in supply, says Ashish Parthasarthy, treasurer at HDFC Bank

The debt woes of India's top business houses are not over even 8 years after the Lehman crisis and their profit growth remains anaemic

The debt woes of India's top business houses are not over even 8 years after the Lehman crisis and their profit growth remains anaemic